The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant cemiplimab plus cetuximab prior to salvage surgery for recurrent oral cavity squamous cell carcinoma.
 
Luana Guimaraes de Sousa
Consulting or Advisory Role - Coherus Biosciences
Research Funding - Agenus (Inst); Regeneron (Inst)
 
Michelle Williams
No Relationships to Disclose
 
Wenli Dong
No Relationships to Disclose
 
Anna Lee
No Relationships to Disclose
 
Kim Learned
No Relationships to Disclose
 
Neil Gross
Honoraria - American Institute of Continuing Medical Education; OncLive/MJH Life Sciences
Consulting or Advisory Role - Geovax Labs; Merck; PDS Biotechnology; Regeneron
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Merck
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Johnson & Johnson/Janssen; Labcorp Drug Development; Pyxis; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Avacta Life Sciences (Inst); Bicara Therapeutics (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics